泰坦科技公告称，公司于2025年7月23日审议通过收购议案，拟使用自有或自筹资金收购CentralGlass日 本持有的Apollo Scientific Ltd. 100%股权。公司已完成相关境外投资备案及审批程序，通过英国投资国 家安全审查。近日，各方签署《交割确认书》，公司已支付全部股权收购款。交割完成后，Apollo Scientific成为公司全资子公司。不过，交易存在外汇汇兑损失、整合成效不确定等风险。 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 一、本次投资概述 上海泰坦科技股份有限公司（以下简称"公司"）于2025年9月25日披露《关于认购创业投资基金份额的 公告》（公告编号：2025-041），公司拟作为有限合伙人以自有资金2,900万元人民币认购上海泰礼璟 源创业投资合伙企业（有限合伙）（以下简称"接力基金第七期"或"合伙企业"）份额。 证券代码：688133 证券简称：泰坦科技 公告编号：2025-048 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 上海泰礼璟源创业投资合伙企业（有限合伙） 上海泰坦科技股份有限公司董事会 公司将密切关注合伙企业后续经营管理状况，敦促其加强投资管理及风险控制，切实降低投资风险，并 严格按照信息披露管理相关规定及时履行信息披露义务。敬请广大投资者注意投资风险。 特此公告。 根据《上海证券交易所科创板股票上市规则》《上海泰坦科技股份有限公司章程》及《对外投资管理制 度》等相关规定，本次对外投资已经公司总经理批准，无需提交公司董事会及股东大会审议。本次投资 不属于关联交易，亦不 ...

证券代码：688133 证券简称：泰坦科技 公告编号：2025-048 接力基金第七期首关认缴出资为 24,200 万元，其中公司拟作为有限合伙人以 自有资金出资人民币 2,900 万元认购接力基金第七期 11.9835%的财产份额。待基 金完成最终募集后，基金总认缴出资额不超过 40,000 万元，其中泰坦科技认缴出 资额保持 2900 万元。合伙企业的出资额、合伙人名册及出资比例等信息以工商登 记为准。 上述投资具体内容详见公告。 二、进展情况介绍 上海泰坦科技股份有限公司 关于对外投资进展暨完成工商登记的公告 一、本次投资概述 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海泰坦科技股份有限公司（以下简称"公司"）于 2025 年 9 月 25 日披露 《关于认购创业投资基金份额的公告》（公告编号：2025-041），公司拟作为有 限合伙人以自有资金 2,900 万元人民币认购上海泰礼璟源创业投资合伙企业（有 限合伙）（以下简称"接力基金第七期"或"合伙企业"）份额。 根据《上海证券交易所科创板股票上市规则》《上 ...

泰坦科技公告，公司作为有限合伙人以自有资金2900万元人民币认购上海泰礼璟源创业投资合伙企业 （有限合伙）份额。接力基金第七期首关认缴出资为2.42亿元，泰坦科技认购11.9835%的财产份额。待 基金完成最终募集后，基金总认缴出资额不超过4亿元，泰坦科技认缴出资额保持2900万元。合伙企业 已完成工商注册登记，出资额为2.42亿元人民币，成立日期为2025年12月15日。 ...

"给公司取名'泰坦'，就是冲着希腊神话里巨人敢扛敢闯的劲儿，想在科学服务领域闯出新路。"谢应波 笑着说，创业后没空打游戏，但一点点磨技能、攒经验直至通关的"进阶劲儿"没丢。"我们心怀成就伟 业的抱负，希望做一家不辜负青春年华、受人尊重的企业。" 从"造自行车"到"造飞机" "经过多年在科学服务行业摸爬滚打，像泰坦科技这样的本土企业，手里早已攥满优质技术和产品，可 真要打破国外品牌'卡脖子'的局面，还需要产业能级的'纵身一跃'。"谢应波一语点透行业进阶的核心痛 点。 谢应波介绍，公司近些年聚焦产业能级建设这一件事，把原先顶多算"造自行车"的制造能级，迭代升级 为"造飞机"，力求打破行业发展的天花板，让本土产品也能撑得起高端场景。 泰坦科技累计服务超过6万家客户、100万科研人员，其中世界500强客户超150家，全国研发型生物医药 企业的覆盖率更是突破八成。 ◎记者 王墨璞嘉 曾长期困于海外技术垄断、受制于产业基础薄弱的国内科学服务行业，如今正迎来本土企业突围的澎湃 浪潮。这场"科学服务突围战"的关键破局者，正是泰坦科技。 从2007年萌芽于华东理工大学宿舍的大学生创业项目，到2020年登陆科创板成为"科学服务第 ...

浦江蜿蜒，润泽上海多个产业园区；浪涛汹涌，击打出创新的节拍；货轮远航，驶向广阔的国际市 场……"十五五"规划建议擘画出未来五年的战略蓝图，一批上海科创公司为国担当、勇为尖兵，瞄准创 新与国际化"双线突围"，谋篇布局高质量发展。 硬核创新是扎根本土的底气。上海完善的科创生态，为企业攻坚"卡脖子"技术提供了肥沃土壤。乘着上 海支持创新创业的东风，80后的大学生创业者谢应波带领泰坦科技，在科学服务行业闯出一条国产化之 路；从生物材料到生物制造，凯赛生物手握颠覆性创新技术，大胆挺进合成生物产业蓝海；面对"数据 危机"带来的挑战，英方软件接连翻越研发、市场与信任"三座山"，以硬实力打造数据"保险栓"；20年 精耕细作，从3G到6G，创远信科不断夯实通信测试技术底座，用"工业之尺"刻画着产业新高度。 开放布局是链接全球的桥梁。依托上海国际科创中心的优势，科创企业家不约而同将未来五年的发展目 光投向国际市场。凯赛生物董事长刘修才说，公司要成为世界生物制造产业的开拓者，并培养中国生物 制造的同路人。在泰坦科技的"征途墙"上，董事长谢应波为"十五五"之路贴上了一个新的关键词 ——"出海"。面对海外客户对中国基础软件的偏见，英方 ...

证券代码：688133 证券简称：泰坦科技 公告编号：2025-047 上海泰坦科技股份有限公司 关于董事离任暨选举职工董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 上海泰坦科技股份有限公司（以下简称"公司"）董事会于近日收到董 事定高翔先生的书面辞职报告。因公司治理结构调整及工作安排调整原因，定高 翔先生申请辞去董事职务，根据《中华人民共和国公司法》（以下简称"《公司 法》"）和《公司章程》的有关规定，定高翔先生的辞职报告自送达公司董事会 时生效。 2025 年 12 月 5 日，公司召开职工代表大会，选举顾梁先生担任公司第 四届董事会职工董事，任期自职工代表大会选举之日起至第四届董事会任期届满 之日止。 (二) 离任对公司的影响 定高翔先生的离任不会导致公司董事会人数低于法定人数，不会影响公司董 事会的正常运作，不会对公司日常生产经营等产生不利影响。其不存在未履行完 毕的公开承诺。 二、职工董事选举情况 根据《中华人民共和国公司法》《上市公司章程指引》等法律法规和规范性 文件及《公司章程》的相 ...

Summary of Conference Call Records Industry Overview - The medical device industry is experiencing overall performance pressure in 2025, but third-quarter revenues have shown a year-on-year increase, with a narrowing decline in net profit attributable to the parent company, primarily due to domestic medical insurance cost control and geopolitical influences. It is expected that normal growth rates will resume in 2026 [1][3][8]. Key Points on Medical Device Sector - **Domestic Market Dynamics**: The slowdown in hospital bidding in 2024 is impacting revenue realization, with an expected boost from the "old-for-new" policy by the end of 2025. The In Vitro Diagnostics (IVD) sector is under pressure due to centralized procurement price adjustments and tax reimbursements [1][4]. - **International Market Challenges**: Companies are strengthening their overseas presence, but initial high costs are pressuring short-term profits. The impact of US-China tariffs on low-value consumables is significant, with expectations of price recovery in the glove industry from late 2025 to 2026 after inventory digestion [1][4][11]. - **Performance Metrics**: In the first three quarters of 2025, the medical device sector reported revenues of 145.7 billion yuan, a year-on-year decline of 2.4%, and a net profit of 26.5 billion yuan, down 14.4%. However, the third quarter showed a positive revenue trend and a narrowing profit decline [3][15]. Specific Sector Insights - **IVD Sector**: The IVD sector saw a year-on-year decline of 14.5% in the first three quarters, but the third quarter showed improvement with revenues of 11.02 billion yuan, benefiting from the implementation of centralized procurement and the release of DRG/DIP 2.0 [16]. - **High-Value Consumables**: This segment experienced a revenue growth of 6.6% year-on-year, with orthopedics showing a significant growth rate of 18.7%. The recovery in cardiovascular surgeries is driving sales, and the ophthalmology sector presents potential due to low penetration rates [17]. - **Medical Equipment**: The medical equipment sector's revenue remained flat, but profit growth was slightly higher. The imaging equipment sector is benefiting from the "old-for-new" projects, with a notable recovery in the endoscope segment [15]. Vaccine Sector Performance - The vaccine sector faced significant pressure, with revenues declining nearly 50% and profits turning negative. However, there is a quarter-on-quarter improvement trend. Future focus includes the recovery of traditional vaccines and the launch of new pipeline products, such as the domestically produced nine-valent HPV vaccine [2][23]. Life Sciences Upstream Sector - The life sciences upstream sector's performance remained stable, with a year-on-year profit growth of 68% in the third quarter, driven by recovering terminal demand and improved gross margins. The sector is benefiting from the expansion of the biopharmaceutical market and policy support [24]. Regulatory Environment and Challenges - The current regulatory environment emphasizes innovation while ensuring safety and efficacy. Domestic companies face challenges in international certifications, particularly with the FDA and CE, due to quality control issues [20][21][22]. Future Outlook - The industry outlook for 2026 includes a focus on self-sufficiency, innovative devices, and accelerated realization of centralized procurement categories. The recovery of orthopedic products is already evident, and international expansion remains a key area of interest [5][7][19].

Core Viewpoint - Titan Technology's stock has experienced fluctuations, with a year-to-date increase of 23.83% but a recent decline over the past 20 and 60 days, indicating potential volatility in its market performance [1]. Financial Performance - For the period from January to September 2025, Titan Technology reported a revenue of 1.848 billion yuan, representing a year-on-year decrease of 13.06%. However, the net profit attributable to shareholders increased by 15.04% to 11.1678 million yuan [2]. - Cumulative cash dividends since the company's A-share listing amount to 86.6205 million yuan, with 40.1089 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, Titan Technology had 9,293 shareholders, an increase of 20.41% from the previous period. The average number of circulating shares per shareholder decreased by 16.95% to 17,694 shares [2]. Business Overview - Titan Technology, established on October 18, 2007, and listed on October 30, 2020, is based in Shanghai and specializes in providing integrated technical solutions for scientific services, including research reagents, biological consumables, analytical consumables, laboratory instruments, and specialized chemicals. The main revenue sources are research reagents (42.70%), research instruments and consumables (28.42%), and specialized chemicals (26.48%) [1].

Core Viewpoint - Shanghai Titan Technology Co., Ltd. has announced a change in its main office address to enhance internal management and facilitate communication with investors [1] Company Contact Information Changes - The company has updated its main office address while other contact methods, such as the investor hotline, remain unchanged [1] - The new contact address is: No. 258, Lane 3111, Huancheng West Road, Fengxian District, Shanghai, Postal Code: 201402 [1] - The company's website is https://www.titansci.com/ and the investor email is contact@titansci.com [1] - The investor hotline is 021-60878330 and the fax number is 021-60878355 [1]